开发和生物可用性测试一种含有乙醇和乙醇-的阴道水凝:一种基于基乙烯纤维素和基基-β-环氧的新型配方
Peter Takacs1,2, Dávid Rátonyi2,3, Barbara Kozma2,3
1Department of Obstetrics and Gynecology, Division of Urogynecology and Reconstructive Surgery, Eastern Virginia Medical School, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA.
Menopause (New York, N.Y.)
|March 10, 2026
概括
一种新的阴道水凝治疗更年期的生殖尿综合征 (GSM) 是有前途的. 基于基乙纤维素 (HEC) 的配方与乙醇 (E4) 和基-β-环极 (HPβCD) 是安全的,并提高了E4的生物可用性,以改善治疗.
科学领域:
- 妇科和生殖医学 妇科和生殖医学
- 药物输送系统 药物输送系统
- 材料科学 材料科学 材料科学
背景情况:
- 更年期的生殖尿综合征 (GSM) 影响了许多更年期后的女性.
- 像阴道雌激素奶油这样的传统治疗方法在坚持和有效性方面都有局限性.
- 需要新的药物输送系统来改善GSM管理.
研究的目的:
- 开发和评估一种新的基于基乙纤维素 (HEC) 的生物粘合性阴道水凝.
- 该水凝含有乙醇 (E4) 和乙醇-,含有氧-β-环氧 (HPβCD) 作为辅助剂.
- 提高药物保留,生物可用性和患者对GSM治疗的遵从性.
主要方法:
- 制备了水凝配方 (E4/200和E4/200/CN),并对溶解性,稳定性和药物释放性进行了表征.
- 在体外生物相容性使用HaCaT角质细胞和复制的人体阴道上皮质模型 (MTT和LDH测定) 进行了评估.
- 通过使用重建的阴道上皮模型来评估透性.
主要成果:
- 观察到E4和HPβCD之间的稳定1:1复合,改善了药物的溶解性.
- 水凝表现出极好的生物相容性,对阴道上皮细胞没有细胞毒性作用 (P<0.0001).
- 透性测试证实了阴道组织中的E4保留,减少了全身暴露,并确保了持续的药物释放.
结论:
- 含有乙醇的基于HEC和基于HPβCD的阴道水凝是无毒的.
- 该配方增强了埃斯特的生物可用性,确保局部,可控释放,以优化治疗疗效.
- 需要进一步的临床试验来确认体内有效性和长期安全性.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
289
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
289
01:21Intrauterine Drug Delivery Systems
74
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
74
01:27Bioavailability Enhancement: Drug Permeability Enhancement
288
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
288
01:10In Vitro Drug Release Testing: Overview, Development and Validation
463
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
463
01:30Modified-Release Drug Delivery Systems: Bioavailability
74
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
74